AEterna Zentaris: Cetrorelix Trial Meets Primary Endpoint

AEterna Zentaris Inc. … reported that the 043 Thorough QT trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia, met its primary endpoint.
Earth Times